What is the role of direct thrombin inhibitors in the treatment of protein S deficiency?

Updated: Jan 03, 2021
  • Author: Mohammad Muhsin Chisti, MD, FACP; Chief Editor: Perumal Thiagarajan, MD  more...
  • Print

Dabigatran  is another option for treatment of hypercoagulable states. In a post hoc analysis of data from the RECOVER, RE-COVER II, and RE-MEDY trials, Goldhaber et al reported no significant differences in rates of symptomatic VTE/VTE-related deaths between dabigatran etexilate and warfarin in patients with or without thrombophilia. [40]

Specific reversal agents for non–vitamin K antagonist oral anticoagulants are lacking, but idarucizumab, an antibody fragment, is available for reversing the anticoagulant effects of dabigatran.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!